{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-017367","form_type":"8-K","ticker":"NSPR","cik":"0001433607","company_name":"InspireMD, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.849016+00:00","generated_at":"2026-06-15T00:55:12.759162+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"InspireMD announces $42.2M upfront private placement with up to $113.6M total; led by Marshall Wace","bullets":["Gross proceeds of $42.2M upfront; additional $71.4M if milestone-driven warrants exercised in cash.","Investors include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain board members.","Warrants exercisable at $1.3827/share upon FDA approvals or pivotal trial results (4 series, each ~$17.9M).","Net proceeds to fund product/clinical development, regulatory approvals, and U.S. launch of CGuard Prime and SwitchGuard.","Closing expected May 15, 2023; Piper Sandler, A.G.P., LifeSci Capital act as advisors."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-017367","json":"https://secwatch.observer/filing/0001493152-23-017367.json","markdown":"https://secwatch.observer/filing/0001493152-23-017367.md","text":"https://secwatch.observer/filing/0001493152-23-017367.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1433607/000149315223017367/0001493152-23-017367-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1433607/000149315223017367/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:55:12.759162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb715446591a1aaf53118d28b9a087faaeed7206","claim":"InspireMD, Inc. entered into Purchase Agreement valued at approximately $42.2 million (effective 2023-05-12).","evidence_excerpt":"On May 12, 2023, InspireMD, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1433607/000149315223017367/0001493152-23-017367-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Value","value":"approximately $42.2 million"},{"label":"Effective","value":"2023-05-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}